JPRN-UMIN000003157已完成2 期
Phase II study of personalized peptide vaccination in bladder cancer patients progressing after first-line platinum-containing regimen - Phase II study of peptide vaccination in bladder cancer patients progressing after chemotherapy
Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division0 个研究点目标入组 80 人开始时间: 2010年2月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Patients do not accept contraception during the 1st vaccination to 70 days after the last vaccination. 4) Patients who are judged inappropriate for the clinical trial by doctors.
研究者
相似试验
已完成
2 期
A phase II trial of personalized peptide vaccination for nine kinds of cancersProstate cancer, Urothelial cancer, Breast cancer, Lung cancer, Ovarian cancer, Gastric cancer, Colon cancer, Liver cancer, Pancreatic cancerJPRN-UMIN000029789Kurume University900
已完成
2 期
A phase II trial of personalized peptide vaccination for rare cancer or primary unknown cancer patientsJPRN-UMIN000014855Kurume University Cancer Vaccine Center200
已完成
2 期
A phase II trial of personalized peptide vaccination for several cancer patients with slight bone marrow suppressioCancer patients who are under standard treatments or resistant to standard treatments with slight bone marrow suppressionJPRN-UMIN000019390Kurume University Cancer Vaccine Center1,000
已完成
不适用
Phase I study of personalized peptide vaccination with transdermal adjuvant for cancer patientsmalignant tumorJPRN-UMIN000030854Kurume University10
已完成
1 期
A phase I trial of personalized peptide vaccination using long and short peptides in patients with metastatic cancer resistant to standard treatmentsMetastatic cancer resistant to standard treatmentsJPRN-UMIN000013029Kurume University Cancer Vaccine Center10